Research output per year
Research output per year
Fingerprint
Dive into the research topics where Do-Youn Oh is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
Oh, D. Y., He, A. R., Bouattour, M., Okusaka, T., Qin, S., Chen, L. T., Kitano, M., Lee, C. K., Kim, J. W., Chen, M. H., Suksombooncharoen, T., Ikeda, M., Lee, M. A., Chen, J. S., Potemski, P., Burris, H. A., Ostwal, V., Tanasanvimon, S., Morizane, C. & Zaucha, R. E. & 23 others, , Aug 2024, In: The Lancet Gastroenterology and Hepatology. 9, 8, p. 694-704 11 p.Research output: Contribution to journal › Article › peer-review
6 Scopus citations -
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
all the NETTER-2 Trial Investigators, 29 Jun 2024, In: The Lancet. 403, 10446, p. 2807-2817 11 p.Research output: Contribution to journal › Article › peer-review
8 Scopus citations -
An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202
Vogel, A., Sahai, V., Hollebecque, A., Vaccaro, G. M., Melisi, D., Al Rajabi, R. M., Paulson, A. S., Borad, M. J., Gallinson, D., Murphy, A. G., Oh, D. Y., Dotan, E., Catenacci, D. V., Van Cutsem, E., Lihou, C. F., Zhen, H., Veronese, M. L. & Abou-Alfa, G. K., Jun 2024, In: ESMO Open. 9, 6, 103488.Research output: Contribution to journal › Article › peer-review
Open Access -
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
DESTINY-PanTumor01 study group, Jun 2024, In: The Lancet Oncology. 25, 6, p. 707-719 13 p.Research output: Contribution to journal › Article › peer-review
4 Scopus citations -
Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023
Kitagawa, Y., Matsuda, S., Gotoda, T., Kato, K., Wijnhoven, B., Lordick, F., Bhandari, P., Kawakubo, H., Kodera, Y., Terashima, M., Muro, K., Takeuchi, H., Mansfield, P. F., Kurokawa, Y., So, J., Mönig, S. P., Shitara, K., Rha, S. Y., Janjigian, Y. & Takahari, D. & 43 others, , May 2024, In: Gastric Cancer. 27, 3, p. 401-425 25 p.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations